Tietze I N, Sørensen S S, Ivarsen P R, Nielsen C B, Pedersen E B
Research Laboratory of Nephrology and Hypertension, Aarhus University Hospital, Skejby Hospital, Denmark.
J Hypertens. 1997 May;15(5):551-60. doi: 10.1097/00004872-199715050-00012.
To determine whether hyperfiltration induced by amino acid infusion can be influenced by angiotensin converting enzyme (ACE) inhibition.
We studied the acute effects of ramipril in 12 healthy control subjects and in 14 patients with essential hypertension. We studied also the effects of 2 months' treatment with ramipril inn 12 patients with essential hypertension and performed a time-control study without amino acids infusion with 12 control subjects. The glomerular filtration rate (GFR), renal plasma flow (RPF), fractional excretion of sodium (FENa) and fractional excretion of lithium (FELi) were determined during 6 clearance periods of 30 min each and amino acids infusion was administered during the last four periods. Plasma concentrations of angiotensin II, aldosterone, atrial natriuretic peptide (ANP), arginine vasopressin, insulin and glucagon were determined.
Both the GFR and the RPF increased markedly in healthy subjects after amino acid infusion both with (GFR 7%, RPF 7%) and without ramipril (GFR 7%), RPF 8%), both P < 0.05. Ramipril administered acutely to essential hypertensives prevented the amino acid-induced increase in RPF [with ramipril 5% (NS), without ramipril 9% (P < 0.05)]. The GFR increased equally with (5%) and without (8%) ramipril (P < 0.20). ACE inhibition after 2 months' treatment of essential hypertension blunted the amino acid-induced increase both in GFR and in RPF [with ramipril GFR 5% and RPF 3% (NS), without ramipril GFR 12%, RPF 11% (P < 0.05)]. The FENa did not change in all four experiments. The FELi, insulin and glucagon increased to the same extent in the first three experiments. ANP increased (P < 0.05) in control subjects both with and without ramipril; angiotensin II and aldosterone decreased significantly in control subjects without ramipril.
The renal haemodynamic response both after acute and after short-term ACE inhibition is attenuated in essential hypertension. Presumably, this treatment makes the arterioles at the glomeruli unresponsive to subsequent amino acid infusion. This inhibition of hyperfiltration might be an important mechanism for the renal protective effect of ACE inhibition in some renal diseases.
确定氨基酸输注诱导的超滤是否会受到血管紧张素转换酶(ACE)抑制的影响。
我们研究了雷米普利对12名健康对照者和14名原发性高血压患者的急性影响。我们还研究了雷米普利对12名原发性高血压患者进行2个月治疗的效果,并对12名对照者进行了无氨基酸输注的时间对照研究。在6个各为30分钟的清除期内测定肾小球滤过率(GFR)、肾血浆流量(RPF)、钠分数排泄率(FENa)和锂分数排泄率(FELi),并在最后四个时期进行氨基酸输注。测定血浆中血管紧张素II、醛固酮、心房利钠肽(ANP)、精氨酸加压素、胰岛素和胰高血糖素的浓度。
在健康受试者中,无论有无雷米普利,氨基酸输注后GFR和RPF均显著增加(有雷米普利时GFR增加7%,RPF增加7%;无雷米普利时GFR增加7%,RPF增加8%),两者P均<0.05。对原发性高血压患者急性给予雷米普利可防止氨基酸诱导的RPF增加[有雷米普利时增加5%(无统计学意义),无雷米普利时增加9%(P<0.05)]。有雷米普利时GFR增加5%,无雷米普利时增加8%(P<0.20)。对原发性高血压患者进行2个月治疗后给予ACE抑制可减弱氨基酸诱导的GFR和RPF增加[有雷米普利时GFR增加5%,RPF增加3%(无统计学意义),无雷米普利时GFR增加12%,RPF增加11%(P<0.05)]。在所有四个实验中FENa均未改变。在前三个实验中FELi、胰岛素和胰高血糖素的增加程度相同。无论有无雷米普利,对照者中ANP均增加(P<0.05);无雷米普利时对照者中血管紧张素II和醛固酮显著降低。
在原发性高血压中,急性和短期ACE抑制后的肾血流动力学反应均减弱。据推测,这种治疗使肾小球处的小动脉对随后的氨基酸输注无反应。这种对超滤的抑制可能是ACE抑制在某些肾脏疾病中发挥肾脏保护作用的重要机制。